ARTICLE | Clinical News
Semuloparin: Phase III data
November 1, 2010 7:00 AM UTC
Top-line data from the double-blind, international Phase III SAVE-ABDO trial showed that 20 mg once-daily semuloparin for 7-10 days after surgery missed the primary endpoint of non-inferiority to 40 m...